Literature DB >> 1730972

Cyclic oral phosphate and etidronate increase femoral and lumbar bone mineral density and reduce lumbar spine fracture rate over three years.

E B Silberstein1, W Schnur.   

Abstract

We have performed a study of the safety and efficacy of cyclic sequential oral phosphate, diphosphonate and calcium carbonate. Forty-two postmenopausal women with osteoporosis diagnosed by dual-photon absorptiometry were treated with a sequential cyclic regimen of oral phosphate for 3 days, etidronate for 2 wk, and then a calcium salt for 12 wk. This was repeated cyclically for 3 yr. They were rescanned after every two 101-day cycles. A control group of 20 patient receiving only the calcium salt was matched for age, time since menopause, race and sex. The group treated with cyclic phosphate, etidronate, and calcium regimen had 80% fewer fractures than the control group over 3 yr of follow-up. Significant response in halting bone mineral loss and increasing bone mineral density was seen in none of the controls but in 90% of treated patients' lumbar spine and 70%-80% of the three regions of the femoral neck examined.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1730972

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  7 in total

1.  Calcitonin versus etidronate for the treatment of postmenopausal osteoporosis: a meta-analysis of published clinical trials.

Authors:  J M Cardona; E Pastor
Journal:  Osteoporos Int       Date:  1997       Impact factor: 4.507

Review 2.  New bisphosphonates in osteoporosis.

Authors:  H Fleisch
Journal:  Osteoporos Int       Date:  1993       Impact factor: 4.507

3.  Total and regional bone mineral content and fracture rate in postmenopausal osteoporosis treated with salmon calcitonin: a prospective study.

Authors:  H Rico; M Revilla; E R Hernández; L F Villa; M Alvarez de Buergo
Journal:  Calcif Tissue Int       Date:  1995-03       Impact factor: 4.333

Review 4.  Etidronic acid. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.

Authors:  C J Dunn; A Fitton; E M Sorkin
Journal:  Drugs Aging       Date:  1994-12       Impact factor: 3.923

5.  Clinical experience with etidronate in osteoporosis.

Authors:  P J Ryan; I Fogelman
Journal:  Clin Rheumatol       Date:  1994-09       Impact factor: 2.980

6.  Effect of vitamin D on bone mineral density of elderly patients with osteoporosis responding poorly to bisphosphonates.

Authors:  George A Heckman; Alexandra Papaioannou; Rolf J Sebaldt; George Ioannidis; Annie Petrie; Charlie Goldsmith; Jonathan D Adachi
Journal:  BMC Musculoskelet Disord       Date:  2002-02-08       Impact factor: 2.362

7.  Effects of cyclical etidronate combined with calcitriol versus cyclical etidronate alone on spine and femoral neck bone mineral density in postmenopausal osteoporotic women.

Authors:  T Masud; B Mulcahy; A V Thompson; S Donnelly; R W Keen; D V Doyle; T D Spector
Journal:  Ann Rheum Dis       Date:  1998-06       Impact factor: 19.103

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.